Trial Profile

A retrospective study of efficacy and safety of intravenous (IV) edaravone compared with those who were not treated with IV edaravone

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 23 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Edaravone (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions; Therapeutic Use

Most Recent Events

31 Oct 2025 According to Tanabe Pharma Corporation, Mitsubishi Tanabe Pharma America is now called Tanabe Pharma America.
15 Aug 2022 According to a Mitsubishi Tanabe Pharma Canada media release, results from this trial were published in eClinicalMedicine, part of The Lancet.
15 Aug 2022 Results (n=318) published in the Mitsubishi Tanabe Pharma Canada Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com